Use of allopurinol to reduce hepatotoxicity from 6-mercaptopurine (6-MP) in patients with acute lymphoblastic leukemia (ALL)

Leuk Lymphoma. 2020 May;61(5):1246-1249. doi: 10.1080/10428194.2019.1702183. Epub 2019 Dec 16.

Authors

Austin J Stuckert¹, Eric S Schafer¹, M Brooke Bernhardt¹, Patricia Baxter¹, Julienne Brackett¹

Affiliation

¹ Texas Children's Cancer Center and Hematology Center, Texas Children's Hospital and Baylor College of Medicine, Houston, TX, USA.

PMID: 31842647
DOI: 10.1080/10428194.2019.1702183

No abstract available

Publication types

Letter

MeSH terms

Allopurinol / adverse effects
Chemical and Drug Induced Liver Injury* / diagnosis
Chemical and Drug Induced Liver Injury* / epidemiology
Chemical and Drug Induced Liver Injury* / etiology
Drug-Related Side Effects and Adverse Reactions*
Humans
Mercaptopurine / adverse effects
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Allopurinol
Mercaptopurine